Pharmacological inhibition in the ataxia telangiectasia and Rad3-similar protein serine/threonine kinase (ATR; generally known as FRAP-relevant protein (FRP1)) has emerged as being a promising system for cancer treatment method that exploits synthetic lethal interactions with proteins linked to DNA injury mend, overcomes resistance to other therapies and enhances antitumour immunity. https://hamidb344teo7.daneblogger.com/profile